Emergence of bullous pemphigoid under treatment of mycosis fungoides with mogamulizumab

Emergence of bullous pemphigoid under treatment of mycosis fungoides with mogamulizumab

Abstract Mycosis fungoides (MF) is the most common cutaneous T cell lymphoma. Since 2018, mogamulizumab, an antibody directed to to the chemokine receptor CCR4, is licensed for the treatment of MF. Treatment with mogamulizumab is associated with the precipiation of different types of skin rashes sum...

Full description

Saved in:
Bibliographic Details
Main Authors: Lukas D. Uleer, Carmen Loquai, Iakov Shimanovich, Cyrus Khandanpour, Jasper N. Pruessmann, Patrick Terheyden, Christian D. Sadik
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:JEADV Clinical Practice
Subjects:
drug side‐effects
mogamulizumab
mogamulizumab‐associated rash
mycosis fungoides
pemphigoid
Online Access:https://doi.org/10.1002/jvc2.570
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/jvc2.570

Similar Items